#Checkmate8HW

Vall d’Hebron Institute of Oncology

@vhio.bsky.social

6 months ago

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer - ecancer Dr Elena Elez speaks to ecancer about the health-related quality of life analyses from CheckMate 8HW. This clinical trial explores nivolumab plus ipilimumab

#ESMOGI25 | Dr. Elena Elez shares insights with @ecancer.org on the #CheckMate8HW trial 🔬

Watch the video here 👇

OncoDaily

@oncodaily.bsky.social

8 months ago

CheckMate 8HW Trial in MSI-H/dMMR mCRC: ESMO GI 2025 The CheckMate 8HW trial presented at ESMO GI 2025 showed improvements in health-related quality of life for patients with MSI-H/dMMR mCRC

ESMO GI 2025 Highlights: CheckMate 8HW Trial on HRQoL in MSI-H/dMMR mCRC with NIVO + IPI
@myesmo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGI25 #CheckMate8HW #mCRC #ColorectalCancer

Oncology's Green Light!

@oncologygreenlight.bsky.social

10 months ago

Oncology's Green Light Podcast · OncologyResearch · FDA Approvals: AI-Powered Insights for everyday oncology clinicians

🎧 Stay informed and join the conversation! #ColorectalCancer #Immunotherapy #MSIH #dMMR #FDAapproval #Oncology #CheckMate8HW #MedicalInnovation #FDA #Nivolumab #Ipilimumab
open.spotify.com/show/6yKyfXw...

CathyEngMD

@cathyengmd.bsky.social

11 months ago

Happened this week: @FDA approves Nivo/Ipi vs. Nivo alone for #MSIhigh or #dMMR met #colorectal #cancer #Checkmate8HW
☑️Median PFS was NR in the combo arm vs. 39.3M (HR = 0.62 [95% CI: 0.48, 0.81]
☑️ORR = 71% vs. 58% (p-value 0.0011)
#CancerResearch #immunotherapy @bristolmyerssquibb.bsky.social

i3 Health

@i3health.bsky.social

1 year ago

Clinic Conversation: CheckMate 8HW Study and the Future of Immunotherapy in Colorectal Cancer YouTube video by Oncology Data Advisor

How will the CheckMate 8HW trial impact the treatment of metastatic colorectal cancer (MSI-H/dMMR)? Dr. Christopher Lieu breaks it down in this Clinic Conversation of the Week.

Read the full interview: www.youtube.com/watch?v=j2Hm...

#ClinicConversation #CheckMate8HW #ColorectalCancer

Oncology Brothers

@oncbrothers.bsky.social

1 year ago

5. #Checkmate8HW: Ph 3, dMMR/MSI-H unresectable or mCRC, Ipi (1mg/kg) + Nivo (240mg) Q3W for 4 cycles and then Nivo alone vs Nivo:

- mPFS NR for Ipi/Nivo vs 39·3 months
- ORR: 71% vs 58%
- Any grade AEs 81% from Ipi/Nivo vs 71% Nivo alone. 3 Rx related deaths.

6/8

Vall d’Hebron Institute of Oncology

@vhio.bsky.social

1 year ago

🗞️ Recently published in NEJM, the phase 3 open-label #CheckMate8HW results demonstrate that first-line immunotherapy combination improves outcomes in patients with metastatic #ColorectalCancer versus chemotherapy

➡️ https://linke.to/Checkmate8HWNEJMVHIO